CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company will hold one-on-one / group meetings with investors in London as part of a Non-Deal Roadshow organized by Kotak Institutional Equities from 12th March, 2024 to 14th March, 2024. CIPLA LTD. - 500087 - Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015
Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we herein mention the schedule of Analyst / Institutional Investor Meetings with the Company.
Cipla stock gains; US FDA inspection concludes with zero observations
Cipla has completed the transfer of its generics business 'as a going concern on a slump sale basis to Cipla Pharma and Life Sciences Limited', the company told bourses CIPLA LTD. - 500087 - Update On Transfer Of Generics Business Undertaking Of The Company To Cipla Pharma And Life Sciences Limited, Wholly Owned Subsidiary
Update on transfer of Generics Business Undertaking of the Company to Cipla Pharma and Life Sciences Limited, wholly owned subsidiary of the Company CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Updates on Acquisition
Update on incorporation of a joint venture company in USA CIPLA LTD. - 500087 - USFDA Inspection At Manufacturing Facility In Qidong, Jiangsu Province, China
USFDA inspection at manufacturing facility in Qidong, Jiangsu Province, China CIPLA LTD. - 500087 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Pursuant to Regulation 39(3) and other applicable regulations of the SEBI (listing obligation and disclosure requirements) Regulations, 2015, we would like to inform you that the Registrar and Share Transfer agent of the Company M/S KFin Technologies Limited has received intimation for loss of share certificate and request for issuance of duplicate share certificates
Cipla Gets CDSCO Nod For Antibiotic To Treat Complicated Urinary Tract Infections
Plazomicin is a new intravenous (IV) aminoglycoside indicated for the treatment of Complicated Urinary Tract Infections, including pyelonephritis. CIPLA LTD. - 500087 - Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS
In compliance with the provisions of Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby notify that the Operations and Administrative Committee of the Company on 15th February, 2024 has allotted 5,863 fully paid-up equity shares of INR 2 each, pursuant to exercise of ESOPs / ESARs under the Employee Stock Option Scheme 2013-A and Cipla Employee Stock Appreciation Rights Scheme 2021 of the Company. Consequently, the issued, subscribed and paid-up share capital of the Company stands increased to INR 1,61,47,30,808 comprising of 80,73,65,404 equity shares of face value INR 2 each.